Companies · Biotechnology

G-Con Manufacturing, Inc.

COLLEGE STATION · Biotechnology

Diligence memoA one-page analyst read on G-Con Manufacturing, Inc. — recommendation, valuation, rhythm, risks.
$13.0M
Total raised · real
3
Rounds
1.7×
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Wed May 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

G-Con Manufacturing, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Dormant
  • Last raise 7.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

G-Con Manufacturing, Inc. is one of 4293 Biotechnology companies tracked from COLLEGE STATION. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2014
Year incorporated
2019-05-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2014-06-09 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2014Series A · 2018-03-13 Raised $3.0M (real) Modeled valuation $108M (est)$3.0M$108MSeries A2018Series A · 2019-05-15 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2019+$3.0M+$5.0MCumulative $13M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2014
Series A extension$3.0M · 2018
Series A extension$5.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$180.8M
Base estimate est.
$5.5M
Conservative case
$982.8M
Upside case
$22.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2014-06-092014Series A · modeled $108.5M · 2018-03-13Series A · modeled $180.8M · 2019-05-152019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
30 mo
Avg between rounds
$2.6M/yr
Capital velocity
12.1 yr
On record since
2014
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.8× above median
This company$13.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.8× above median
This company$180.8M
Sector median$64.2M

Raised more than 61% of sector peers (real $). Modeled value above 71% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 216.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)G-Con Manufacturing, Inc. (this company) Raised $13.0M · modeled $180.8M (est)G-Con Manufacturing, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
G-Con Manufacturing, Inc. this companySeries A$13.0M$180.8M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2014-06-09$22.7M$180.8M85%
Series A$3.0M2018-03-13$13.6M$108.5M90%
Series A$5.0M2019-05-15$22.7M$180.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2014-06-09
    • First recorded raise — entered as Series A.
    • 1 investor on this round.
  2. Series A$3.0M2018-03-13
    • Raised again after 45 mo — slower than the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  3. Series A$5.0M2019-05-15
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~30mo cadence
$8.3M
Modeled next size est.range $5.4M$13.3M
1.7×
Last step-up
$2.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Shanahan2 other2019-05
David M. Shanahan1 other2014-06
Robert P. Landin1 other2014-06
Lloyd P Thompson2019-05
Maik Jornitz2018-03
Maik P. Jornitz2014-06
Melissa P. Hall2018-03
Paul P Moore2019-05
Robert P. Williams2018-03
Sidney P. Backstrom2018-03
Thomas P. Lyles2018-03
William P Burkoth2018-03
Registry & provenance

G-Con Manufacturing, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1611431
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gradalis, Inc.BiotechnologySeries C$56.7M$79.7Mnetwork3 shared operators · same sector
EnGeneIC Ltd. (ABN: 59 091 336 499)BiotechnologySeries A$13.0M$144.6Msame sector · same stage
Cerium Pharmaceuticals, Inc.BiotechnologySeries A$13.1M$193.4Msame sector · same stage
Gemin X Pharmaceuticals IncBiotechnologySeries A$13.2M$141.6Msame sector · same stage
Cellinfinity Bio Holding Company, LLCBiotechnologySeries A$13.2M$216.2Msame sector · same stage
Tissue Regeneration Systems IncBiotechnologySeries A$13.2M$148.0Msame sector · same stage
Insilico Medicine, Inc.BiotechnologySeries A$12.8M$216.9Msame sector · same stage
Arcturus Therapeutics, Inc.BiotechnologySeries A$13.3M$214.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
GPB Scientific, LLCBiotechnologySeries B$59.6M88%
GlycosBio Inc.BiotechnologySeries A$6.9M88%
Globin Solutions, Inc.BiotechnologySeries A$162.7M88%
Glycomine, Inc.BiotechnologySeries A$178.4M87%
Gnosko Bio Inc.BiotechnologyPre-Seed$512K87%
G.I. Windows, Inc.BiotechnologySeries B$218.3M86%
Gliacure, Inc.BiotechnologySeries A$57.0M86%
GRI Bio, Inc.BiotechnologySeries B$4.8M86%
Frequently asked
How much funding has G-Con Manufacturing, Inc. raised?
G-Con Manufacturing, Inc. has raised approximately $13.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is G-Con Manufacturing, Inc.'s estimated valuation?
Provath's modeled valuation for G-Con Manufacturing, Inc. is approximately $180.8M (modeled range $5.5M–$982.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is G-Con Manufacturing, Inc. at?
G-Con Manufacturing, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed May 15.
What does G-Con Manufacturing, Inc. do and where is it based?
G-Con Manufacturing, Inc. operates in the Biotechnology sector, based in COLLEGE STATION.
Explore related

See where G-Con Manufacturing, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at G-Con Manufacturing, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.